|
1
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Youlden DR, Cramb SM and Baade PD: The
international epidemiology of lung cancer: geographical
distribution and secular trends. J Thorac Oncol. 3:819–831. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Normanno N, Maiello MR and De Luca A:
Epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs): simple drugs with a complex mechanism of action? J
Cell Physiol. 194:13–19. 2003. View Article : Google Scholar
|
|
4
|
Hynes NE and Lane HA: ERBB receptors and
cancer: the complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mitsudomi T, Morita S, Yatabe Y, et al:
Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): an open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
|
|
7
|
Maemondo M, Inoue A, Kobayashi K, et al:
Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou C, Wu YL, Chen G, et al: Erlotinib
versus chemotherapy as first-line treatment for patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase
3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rosell R, Carcereny E, Gervais R, et al:
Erlotinib versus standard chemotherapy as first-line treatment for
European patients with advanced EGFR mutation-positive
non-small-cell lung cancer (EURTAC): a multicentre, open-label,
randomised phase 3 trial. Lancet Oncol. 13:239–246. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pao W, Miller VA, Politi KA, et al:
Acquired resistance of lung adenocarcinomas to gefitinib or
erlotinib is associated with a second mutation in the EGFR kinase
domain. PLoS Med. 2:e732005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kobayashi S, Boggon TJ, Dayaram T, et al:
EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fujita Y, Suda K, Kimura H, et al: Highly
sensitive detection of EGFR T790M mutation using colony
hybridization predicts favorable prognosis of patients with lung
cancer harboring activating EGFR mutation. J Thorac Oncol.
7:1640–1644. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Su KY, Chen HY, Li KC, et al: Pretreatment
epidermal growth factor receptor (EGFR) T790M mutation predicts
shorter EGFR tyrosine kinase inhibitor response duration in
patients with non-small-cell lung cancer. J Clin Oncol. 30:433–440.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rosell R, Molina MA, Costa C, et al:
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in
erlotinib-treated advanced non-small-cell lung cancer patients with
EGFR mutations. Clin Cancer Res. 17:1160–1168. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shepherd FA, Douillard JY and Blumenschein
GR Jr: Immunotherapy for non-small cell lung cancer: novel
approaches to improve patient outcome. J Thorac Oncol. 6:1763–1773.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rosenberg SA, Yang JC and Restifo NP:
Cancer immunotherapy: moving beyond current vaccines. Nat Med.
10:909–915. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kawakami Y, Wang X, Shofuda T, et al:
Isolation of a new melanoma antigen, MART-2, containing a mutated
epitope recognized by autologous tumor-infiltrating T lymphocytes.
J Immunol. 166:2871–2877. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lennerz V, Fatho M, Gentilini C, et al:
The response of autologous T cells to a human melanoma is dominated
by mutated neoantigens. Proc Natl Acad Sci USA. 102:16013–16018.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yoshikawa T, Nakatsugawa M, Suzuki S, et
al: HLA-A2-restricted glypican-3 peptide-specific CTL clones
induced by peptide vaccine show high avidity and antigen-specific
killing activity against tumor cells. Cancer Sci. 102:918–925.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Valmori D, Fonteneau JF, Lizana CM, et al:
Enhanced generation of specific tumor-reactive CTL in vitro by
selected Melan-A/MART-1 immunodominant peptide analogues. J
Immunol. 160:1750–1758. 1998.PubMed/NCBI
|
|
21
|
Parkhurst MR, Salgaller ML, Southwood S,
et al: Improved induction of melanoma-reactive CTL with peptides
from the melanoma antigen gp100 modified at
HLA-A*0201-binding residues. J Immunol. 157:2539–2548.
1996.PubMed/NCBI
|
|
22
|
Fong L, Hou Y, Rivas A, et al: Altered
peptide ligand vaccination with Flt3 ligand expanded dendritic
cells for tumor immunotherapy. Proc Natl Acad Sci USA.
98:8809–8814. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hirano N, Butler MO, Xia Z, et al:
Engagement of CD83 ligand induces prolonged expansion of
CD8+ T cells and preferential enrichment for antigen
specificity. Blood. 107:1528–1536. 2006. View Article : Google Scholar
|
|
24
|
Yoshimura M, Tada Y, Ofuzi K, Yamamoto M
and Nakatsura T: Identification of a novel
HLA-A*02:01-restricted cytotoxic T lymphocyte epitope
derived from the EML4-ALK fusion gene. Oncol Rep. 32:33–39.
2014.PubMed/NCBI
|
|
25
|
Rubio V, Stuge TB, Singh N, et al: Ex vivo
identification, isolation and analysis of tumor-cytolytic T cells.
Nat Med. 9:1377–1382. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Warren RL and Holt RA: A census of
predicted mutational epitopes suitable for immunologic cancer
control. Hum Immunol. 71:245–254. 2010. View Article : Google Scholar
|
|
27
|
Soverini S, Hochhaus A, Nicolini FE, et
al: BCR-ABL kinase domain mutation analysis in chronic myeloid
leukemia patients treated with tyrosine kinase inhibitors:
recommendations from an expert panel on behalf of European
LeukemiaNet. Blood. 118:1208–1215. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cai A, Keskin DB, DeLuca DS, et al:
Mutated BCR-ABL generates immunogenic T-cell epitopes in CML
patients. Clin Cancer Res. 18:5761–5772. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yamshchikov GV, Barnd DL, Eastham S, et
al: Evaluation of peptide vaccine immunogenicity in draining lymph
nodes and peripheral blood of melanoma patients. Int J Cancer.
92:703–711. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen W, Yewdell JW, Levine RL and Bennink
JR: Modification of cysteine residues in vitro and in vivo affects
the immunogenicity and antigenicity of major histocompatibility
complex class I-restricted viral determinants. J Exp Med.
189:1757–1764. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Meadows L, Wang W, den Haan JM, et al: The
HLA-A*0201-restricted H-Y antigen contains a
posttranslationally modified cysteine that significantly affects T
cell recognition. Immunity. 6:273–281. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shomura H, Shichijo S, Matsueda S, et al:
Identification of epidermal growth factor receptor-derived peptides
immunogenic for HLA-A2(+) cancer patients. Br J Cancer.
90:1563–1571. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shomura H, Shichijo S, Komatsu N, et al:
Identification of epidermal growth factor receptor-derived peptides
recognised by both cellular and humoral immune responses in
HLA-A24+ non-small cell lung cancer patients. Eur J
Cancer. 40:1776–1786. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lu YC, Yao X, Li YF, et al: Mutated
PPP1R3B is recognized by T cells used to treat a melanoma patient
who experienced a durable complete tumor regression. J Immunol.
190:6034–6042. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Robbins PF, Lu YC, El-Gamil M, et al:
Mining exomic sequencing data to identify mutated antigens
recognized by adoptively transferred tumor-reactive T cells. Nat
Med. 19:747–752. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Falk K, Rötzschke O, Stevanović S, Jung G
and Rammensee HG: Allele-specific motifs revealed by sequencing of
self-peptides eluted from MHC molecules. Nature. 351:290–296. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sidney J, Southwood S, Mann DL,
Fernandez-Vina MA, Newman MJ and Sette A: Majority of peptides
binding HLA-A*0201 with high affinity crossreact with
other A2-supertype molecules. Hum Immunol. 62:1200–1216. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Matsushita H, Vesely MD, Koboldt DC, et
al: Cancer exome analysis reveals a T-cell-dependent mechanism of
cancer immunoediting. Nature. 482:400–404. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schirle M, Keilholz W, Weber B, et al:
Identification of tumor-associated MHC class I ligands by a novel T
cell-independent approach. Eur J Immunol. 30:2216–2225. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Parkhurst MR, Riley JP, Igarashi T, Li Y,
Robbins PF and Rosenberg SA: Immunization of patients with the
hTERT:540–548 peptide induces peptide-reactive T lymphocytes that
do not recognize tumors endogenously expressing telomerase. Clin
Cancer Res. 10:4688–4698. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Matar P, Alaniz L, Rozados V, et al:
Immunotherapy for liver tumors: present status and future
prospects. J Biomed Sci. 16:302009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pollack BP, Sapkota B and Cartee TV:
Epidermal growth factor receptor inhibition augments the expression
of MHC class I and II genes. Clin Cancer Res. 17:4400–4413. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
He S, Yin T, Li D, et al: Enhanced
interaction between natural killer cells and lung cancer cells:
involvement in gefitinib-mediated immunoregulation. J Transl Med.
11:1862013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yamada T, Azuma K, Muta E, et al: EGFR
T790M mutation as a possible target for immunotherapy;
identification of HLA-A*0201-restricted T cell epitopes
derived from the EGFR T790M mutation. PLoS One. 8:e783892013.
View Article : Google Scholar
|
